Tripep successfully concludes ChronSeal safety study -efficacy against acute wounds indicates a broader therapeutic use

Tripep successfully concludes ChronSeal safety study -efficacy against acute
wounds indicates a broader therapeutic use

Tripep has successfully concluded a safety study for ChronSeal - Tripep and
Kringle Pharma's jointly owned treatment for chronic leg wounds. The study,
which was conducted to show safety of the new antibiotic free-formulation in
combination with ChronSeal, also showed increased healing of acute skin wounds.
In January 2008, Tripep submitted an application for the initiation of a Phase
II study of ChronSeal. If approval is granted, it is estimated that the study
will start during the first half of 2008.

The successfully concluded study was conducted to show safety of the new
antibiotic free formulation in combination with ChronSeal, Tripep and Kringle
Pharma's hepatocyte growth factor (HGF) based treatment for chronic leg wounds.
Since HGF is normally produced in the body in acute wounds, as opposed to
chronic wounds, the study was only expected to show safety with no biological
effect on  wound healing. However, besides showing that ChronSeal was safe it
was also shown that acute full-thickness wounds healed more rapidly in the
presence of ChronSeal given at concentrations intended for the clinical trial on
chronic leg-wounds planned for this year. 

“The study results are very encouraging and indicate that ChronSeal in the new
antibiotic free formulation is even more potent than we expected. The biological
effect is a very important observation and we look forward to the planned
clinical trial and to further document  ChronSeal's potential”, says Tripep's
CEO Jan Nilsson.

In January 2008, Tripep submitted an application to the Medical Products Agency
for the initiation of a Phase II study of ChronSeal for the treatment of chronic
leg wounds. If approval is granted, it is estimated that the study will start
during the first half of 2008. 

For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63, E-mail:
jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28, E-mail:
anders.vahlne@ki.se


Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's Website: www.tripep.se .